Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting

TUSTIN, Calif., April 11, 2008 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

    --  "Targeting mutant p53 protein and tumor vasculature: An effective

        combination therapy for advanced breast tumors" (Abstract #2341, New

        Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

        April 14, 2008 from 8:00 am to 12:00 pm.


    --  "An immunocytokine that binds to phosphatidylserine generates an

        effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

        Vaccines Session) - Poster session scheduled for Monday, April 14,

        2008 from 1:00 pm to 5:00 pm.


    --  "Combination of a monoclonal anti-phosphatidylserine antibody with

        docetaxel strongly inhibits the growth and metastasis of

        hormone-refractory prostate cancers in mice" (Abstract #2551, New

        Approaches to Biological Therapy Session) - Oral presentation

        scheduled for Monday, April 14, 2008 at 2:10 pm.


    --  "Antibody targeting of phosphatidylserine produces a cytokine

        microenvironment that enhances innate anti-tumor immune responses"

        (Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

        Session) - Poster session scheduled for Tuesday, April 15, 2008 from

        8:00 am to 12:00 pm.


Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

     Contacts:

     GendeLLindheim BioCom Partners

     Investors                              Media

     info@peregrineinc.com                  Barbara Lindheim

     (800) 987-8256                         (212) 918-4650

CONTACT: investors, 1-800-987-8256, , or media,Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners,for Peregrine Pharmaceuticals, Inc. info@peregrineinc.com

Web site: http://www.peregrineinc.com/http://www.aacr.org/

Ticker Symbol: (NASDAQ-NMS:PPHM)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2008

View comments

Hide
(web2)